T reatment of hypertension, hyperlipidemia, and diabetes mellitus and assisting patients with cessation of cigarette smoking are efficacious in preventing first-time 1 and recurrent 2 stroke. The opportunities to favorably influence blood pressure, cholesterol, and other vascular risk factors are substantial. The prevalence in the United States of persons with low risk-factor burden has been <11% for decades. 3 Intensive medical therapy has been associated with a low absolute risk of stroke in patients with asymptomatic carotid stenosis. 4 Intensive statin therapy reduced the risk of any stroke by 33% in the >1000 patients with known carotid disease in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. 5 It is not known how well vascular risk factors are controlled in this population at risk for stroke. The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) is a multicenter randomized clinical trial of carotid stenting versus endarterectomy in patients with symptomatic and asymptomatic carotid disease.
The purpose of this study was to assess whether the methods used in CREST to manage vascular risk factors resulted in improvements in risk-factor status.
Methods
This study involves an exploratory analysis. The CREST trial was approved by the local governing institutional review board of each participating center, and all patients provided written informed consent. The trial methods 6 and primary results 7 have been published. The investigational devices, the Acculink/RX Acculink carotid stent system and the Accunet/RX Accunet, were manufactured by Abbott Vascular, Inc. The primary aim of the trial was to compare 2 types of revascularization procedures, carotid endarterectomy and carotid stenting; however, the investigators recognized that monitoring and medical management of vascular risk factors were essential for patient safety and overall stroke risk reduction. Patients underwent twice-yearly assessments of blood pressure, blood glucose, lipids, and cigarette smoking status for the first 48 months of the trial. The medical treatments were provided by the patient's usual-care physician. The principal investigators and study coordinators at CREST participating centers were instructed to inform the patients' primary care physicians regarding the results of the vascular-risk-factor assessments using a standardized letter. Published American Heart Association guideline statements for levels of control of blood pressure, glucose in diabetic patients, and lipids were adopted studywide and were provided to the usual-care physician. The importance of appropriate concomitant medical therapy was emphasized at CREST investigators and annual coordinators meetings throughout the course of the trial. Studywide control of vascular risk factors was reported to and monitored by the independent data and safety monitoring board appointed by the National Institute of Neurological Disorders and Stroke. For this exploratory analysis, group means and rates for risk factors were calculated using generalized estimating equations (using an unstructured covariance matrix) to account for the differences in sample sizes at each followup visit while still accounting for the repeated measures for Tables 2 and 3 show the status of these risk factors separately for symptomatic and asymptomatic patients. In the period from December 21, 2000, to January 3, 2006, when the first third of patients were enrolled in the trial, the rate of optimal risk-factor control at enrollment was 14%. Table 4 shows the rates of optimal riskfactor control at enrollment by calendar year of enrollment. The proportion of patients achieving optimal control of the 4 risk-factor goals was 14.2% for the years 2000-2004 and rose to >17% over the years 2005-2008, although the improvements over time were not significant. Table 5 shows the change in proportion of all patients achieving targets for vascular risk factors from baseline to 6 months, from baseline to 12 months, from baseline to 24 months, from baseline to 36 months, and from baseline to 48 months. The same outcomes are shown separately for symptomatic and asymptomatic patients in Tables 6 and 7 , respectively. By 6 months, significant improvements were observed for all therapeutic targets. The majority of patients had achieved therapeutic targets for systolic blood pressure, blood glucose, and cigarette smoking; however, less than two thirds of patients achieved LDL cholesterol levels <100 mg/dL. The rates for achieving a target LDL of <70 mg/dL were 22.9% at baseline, 27.4% at 12 months (P=0.0003 versus baseline), and 27.9% at 48 months (P=0.0258 versus baseline). Only 16.7% of patients had optimal risk-factor control at enrollment P values test changes from baseline (note that changes from baseline on smoking are provided in Table 5 ). Patients were considered to be optimally medically managed if they achieved all of the following therapeutic goals: LDL cholesterol <100 mg/dL, glucose <126 mg/dL, systolic blood pressure <140 mm Hg, and no active cigarette smoking.
in the trial, and although the change at 6 months was significant, this rate rose to only 27.1%. Significant benefits in risk-factor control were observed across all risk factors throughout follow-up. 
Discussion
We observed that the majority of participants had control of blood pressure, glucose, and smoking but not LDL cholesterol at the time of enrollment. Very early in the course of participation in the trial, significant improvements were seen for all 4 tracked risk factors. The improvements seen at 6 months of follow-up were sustained for up to 4 years. The statistically significant improvement in risk factors, however, should not obscure the fact that the absolute levels of control of risk factors were far from ideal. Only 28% had achieved optimal risk-factor control by 6 months, and only 35% had achieved it by 48 months. These rates are comparable to the rates of optimal risk-factor control achieved for patients without diabetes and coronary artery disease enrolled in the COURAGE trial and are substantially better than what was achieved for patients with diabetes and coronary artery disease in the COURAGE, BARI 2D, and FREEDOM trials. 10 Our results may not reflect the epidemiology of risk-factor control among patients with carotid stenosis. One would anticipate that risk-factor control is poorer among the general population with carotid stenosis because of the healthyparticipant bias. Consequently, there may be an even greater opportunity to improve vascular risk factors in the general population of patients with carotid atherosclerosis. For patients with coronary artery disease, there is considerable opportunity to improve vascular risk factors. Among the >3000 patients with self-reported coronary artery disease in the REGARDS study, only 16% met all 3 goals for aspirin, blood pressure, and LDL cholesterol.
11
CREST had no treatment group that received only medical therapy. Emphasis in the trial was placed on selecting sites with outstanding surgical and interventional teams and ensuring low risk for periprocedure stroke following either carotid endarterectomy or carotid stenting. The medical management was decentralized, even beyond the site level, because it was often provided by the usual-care physician (generally the referring physician). Accordingly, aggressive and timely control of risk factors by the site or by the CREST central leadership was not feasible. The results of the medical monitoring were provided to the usual-care physician, but whether or not the results were acted on when provided (eg, systolic blood pressures ≥140 mm Hg or LDLs ≥100 mg/dL) or how they were acted on could not be determined.
The enrollment period for CREST was 7.5 years from 2000 until midyear 2008. During this time, risk-factor-management guidelines for primary and secondary prevention of stroke were published and widely disseminated.
1,2 Consequently, it is not surprising that control of risk factors at baseline improved in comparisons of the earlier years of enrollment to the later years. In the secondary prevention trial, Vitamin Intervention for Stroke Prevention (VISP), control of several risk factors at baseline also improved significantly during the 4.4-year recruitment period from August 1997 to December 2001. 12 Hypertension and hypercholesterolemia management and control improved; there was an increase in use of antiplatelet medications, newer classes of antihypertensive medications, and lipid-lowering drugs. 12 Similar to the CREST recruitment period, during the VISP enrollment period, national guidelines were released in addition to results from other secondary prevention trials. For stroke prevention trials with long recruitment periods, it is important that risk-factor management be standardized and be as stable as possible across all treatment groups so as not to differentially reduce the event rate and thus the ability of the trial to detect treatment effects. 13 There is growing interest in conducting a randomized trial to compare intensive medical therapy and revascularization, similar to what has been done for stable coronary disease, 14 atherosclerotic renal artery stenosis, 15 and intracranial cerebrovascular disease. 16 In the Stenting Versus Aggressive
Medical Management for Intracranial Stenosis (SAMMPRIS) study, a centralized model for treatment of risk factors was used. Management of medications for risk factors was provided by the local-site neurologist but was specified in a step-by-step protocol. Adherence to the protocol was monitored and enforced centrally by a SAMMPRIS medical core; lifestyle coaching was also provided by a national provider under direction of the SAMMPRIS medical core. The control of risk factors was exceptional with these methods. At baseline, 4 months, and 1 year, the mean systolic blood pressure was 146.8AE21.8, 134.8AE17.0, and 133.8AE17.1 mm Hg, respectively. For LDL, the results at baseline, 4 months, and 1 year were 97.7AE36.6, 72.8AE26.0, and 68.2AE27.5 mg/dL, respectively. Consequently, along with the results we report in this paper, SAMMPRIS suggests that achieving intensive therapeutic targets with medical therapy may require a tightly integrated organizational model with close central management of a hands-on local medical management team. The soon-to-be-initiated CREST-2 trial of intensive medical management with or without revascularization in patients with asymptomatic carotid stenosis will use such an approach to management of vascular risk factors.
17
The so-called inclusion benefit has not been clearly demonstrated in cancer trials 18 ; however, it may be present in trials like CREST-2, in which proven therapies will be given to all patients adjunctive to the interventions to which the patients are being randomized. We do not know how risk factors changed for patients who were eligible for CREST but who refused participation. Nonetheless, we suspect that patients benefited from being included in the trial because favorable effects were observed across key vascular risk factors. In CREST, adherence to evidence-based guidelines was promoted across clinical centers. Such guidelines have been shown to improve clinical practice. 19 It is both surprising and disappointing that the rates of optimal risk-factor control, although relatively improved, remain poor in an absolute sense. One might have anticipated a greater effect on behaviors of the treating physicians; however, reasons for lack of risk-factor control are multifaceted and involve not only the treating physicians but also other healthcare providers, the healthcare system, and the individual patient. Related reasons include medication noncompliance, inadequate therapy, and inappropriate therapy. A limitation of our study is that data are provided on only 4 metrics for vascular risk factors. Data were not available for other important risk factors such as frequency of exercise or quality of diet. In addition, not every patient enrolled in the study had every follow-up visit, and not every risk factor was assessed at every follow-up visit. Loss to follow-up was more problematic for the later visits than for the earlier visits. Although missing visits did not occur at random, the proportion of missed visits was very low and was unlikely to have altered the basic conclusions that risk factors improved and that optimal risk-factor control was rarely achieved. Cigarette smoking was assessed by self-report and not by objective measures such as the detection of nicotine metabolites in serum; however, smoking status tends to be slightly underestimated by self-report. 20 This implies that the rate of 17% for active smoking at 48 months after randomization conservatively estimates the true active smoking rate.
Conclusion
In conclusion, significant improvements were seen in control of vascular risk factors in patients enrolled in CREST. However, substantial opportunities remained for most patients to further improve upon medical management. Future carotid interventional trials should place increasing emphasis on controlling vascular risk factors.
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